Indridason Olafur S, Franzson Leifur, Sigurdsson Gunnar
Department of Medicine, Landspitali-University Hospital, Reykjavik, Iceland.
Osteoporos Int. 2005 Apr;16(4):417-23. doi: 10.1007/s00198-004-1699-x. Epub 2004 Jul 20.
The purpose of this study was to compare age-related differences in osteoprotegerin (OPG) in relationship with BMD and the serum bone markers osteocalcin (OC), collagen crosslinks (CTX), and tartrate-resistant acid phosphatase 5b (TRACP-5b).
Data were derived from a cross-sectional study on bone health in a random sample of community-dwelling adults aged 30 to 85 years in the Reykjavik area in Iceland. All subjects had whole body, hip, and lumbar spine BMD measured (by DXA), gave blood samples, and answered a thorough questionnaire on medications and medical history. We assessed relationships using the Spearman correlation coefficient, partial correlation, and multivariable linear regression. Men and women were analyzed separately.
Of 2,310 subjects invited over 2 years, 1,630 participated. After excluding individuals with diseases and medications affecting bone metabolism, 517 women (age 56.1 +/- 16.9 years) and 491 men (age 58.7 +/- 14.9 years) remained for analysis. OPG increased steadily with age in both genders without a gender difference. In women, BMD at all sites declined steadily after age 50. In men, BMD remained relatively stable until age 70, after which it declined significantly. After controlling for age, BMI, and other confounding variables, OPG showed only a borderline positive relationship with whole body BMD in men (P = 0.10), but the relationship was nonsignificant in women. In multivariable models, OPG was inversely related to TRACP-5b (P = 0.002) and positively with OC (P = 0.007), the OC/TRACP-5b (P = 0.001) and OC/CTX (P = 0.02) ratios in women. Among men, multivariable models showed a positive association between OPG and OC (P = 0.05) and OC/TRACP-5b (P < 0.009).
We conclude that serum OPG levels are associated with a profile of bone turnover markers favoring bone formation, suggesting that OPG may be protective against age-related bone loss. Longitudinal studies are needed to address that issue.
本研究的目的是比较骨保护素(OPG)与骨密度(BMD)以及血清骨标志物骨钙素(OC)、胶原交联(CTX)和抗酒石酸酸性磷酸酶5b(TRACP-5b)之间的年龄相关差异。
数据来自冰岛雷克雅未克地区30至85岁社区居住成年人随机样本的骨健康横断面研究。所有受试者均测量了全身、髋部和腰椎的骨密度(通过双能X线吸收法),采集了血样,并回答了一份关于药物和病史的详细问卷。我们使用斯皮尔曼相关系数、偏相关和多变量线性回归评估关系。男性和女性分别进行分析。
在两年内邀请的2310名受试者中,1630名参与。排除影响骨代谢的疾病和药物个体后,剩余517名女性(年龄56.1±16.9岁)和491名男性(年龄58.7±14.9岁)进行分析。两性的OPG均随年龄稳步增加,无性别差异。在女性中,50岁后所有部位的骨密度均稳步下降。在男性中,骨密度在70岁前相对稳定,之后显著下降。在控制年龄、体重指数和其他混杂变量后,OPG在男性中与全身骨密度仅呈临界正相关(P = 0.10),但在女性中该关系不显著。在多变量模型中,OPG与女性的TRACP-5b呈负相关(P = 0.002),与OC呈正相关(P = 0.007),与OC/TRACP-5b(P = 0.001)和OC/CTX(P = 0.02)比值呈正相关。在男性中,多变量模型显示OPG与OC(P = 0.05)和OC/TRACP-5b(P < 0.009)呈正相关。
我们得出结论,血清OPG水平与有利于骨形成的骨转换标志物谱相关,提示OPG可能对年龄相关的骨质流失具有保护作用。需要进行纵向研究来解决该问题。